Cytomegalovirus in hematopoietic stem cell transplant recipients.
This article examines the clinical manifestations of and risk factors for cytomegalovirus (CMV). Prevention of CMV infection and disease are also explored. Antiviral resistance and management of CMV are examined.
Ljungman
Per
P
Department of Hematology, Karolinska University Hospital, S-14186 Stockholm, Sweden. Per.Ljungman@ki.se
Hakki
Morgan
M
Boeckh
Michael
M
D000998:Antiviral Agents / Q000627:therapeutic use; D003587:Cytomegalovirus / Q000472:pathogenicity; D003586:Cytomegalovirus Infections / Q000188:drug therapy* / Q000635:transmission*; D018562:Disease Transmission, Infectious; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D016867:Immunocompromised Host; D016219:Immunotherapy, Adoptive / Q000379:methods; D017735:Virus Latency
D000998:Antiviral Agents